文献速递脑血管病

急性缺血性卒中r-tPA治疗趋势及影响因素

Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2020-03-02

r-tPA治疗频率从2006年9.9%升至2018年21.8%,预测2025年达24%;后循环卒中和房颤患者治疗几率随时间分别呈上升和下降趋势。

要点

  • r-tPA治疗频率从2006年9.9%升至2018年21.8%,预测2025年达24%。
  • 高龄、NIHSS 2-3分、后循环、醒后卒中及无房颤患者治疗频率增加明显。
  • 房颤患者r-tPA治疗几率随时间下降,需特别关注。

核心结论

  • r-tPA治疗频率呈积极增长,反映临床对静脉溶栓信心提升,但房颤患者治疗几率下降值得关注。

主要发现

  • 总体r-tPA治疗频率从2006年9.9%升至2018年21.8%。
  • 高龄、NIHSS 2-3分、后循环卒中、醒后卒中及无房颤患者治疗频率增加明显。
  • 预测2025年总体r-tPA频率达24%。
  • 后循环卒中患者r-tPA治疗几率随时间增加,房颤患者治疗几率随时间下降。

临床怎么用

  • 临床实践中可参考r-tPA治疗频率增长趋势,对特定亚组如高龄、后循环卒中及醒后卒中患者更积极评估溶栓。
  • 对房颤患者r-tPA治疗几率下降的现象需进一步关注,避免因合并房颤而减少溶栓考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Frequencies of treatment with r-tPA (recombinant tissue-type plasminogen activator) are increasing over the past 15 years. However, published data on the influence of various demographic and clinical factors on r-tPA treatment as well as estimates of future trajectories are limited. We evaluated time trends and future trajectories of r-tPA treatment in patients with acute stroke and the influence of various factors on r-tPA treatment by analyzing data of 103 970 patients enrolled in the Austrian Stroke Unit Registry from 2006 to 2018, of which 18 953 were treated with r-tPA. Methods- Time trends of r-tPA-treatment were investigated in predefined subgroups (minor/major stroke, age, anterior/posterior circulation stroke); limited exponential time series models were calculated to estimate future trends of r-tPA-treatment. Logistic regression models were calculated to estimate the influence of clinical variables on r-tPA-treatment. Results- Overall, r-tPA treatment frequencies increased from 9.9% in 2006 to 21.8% in 2018. We observed a particular increase in patients >80 years, patients presenting with a National Institutes of Health Stroke Scale Score of 2 to 3, patients with posterior circulation stroke, patients with wake-up stroke, and patients without atrial fibrillation. Forecast of overall r-tPA frequencies predicted a further but flattened increase up to 24% by 2025. Logistic regression of time-dependent associations of clinical variables with r-tPA-treatment revealed increasing odds of r-tPA-treatment in patients with a posterior circulation stroke and decreasing odds of r-tPA-treatment in patients with atrial fibrillation. Conclusions- We observed a positive development of r-tPA-treatment frequencies mirroring increasing confidence with intravenous thrombolysis in clinical practice; however, decreasing odds of r-tPA-treatment over time in patients with atrial fibrillation deserve particular attention.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Marko M, Posekany A, Szabo S, et al. Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke. Stroke. 2020. PMID: 32114931. doi:10.1161/STROKEAHA.119.027921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。